- Home
- TLPH vs PLRX Comparison
TLPH vs PLRX Comparison
Compare TLPH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | PLRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 61.1M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TLPH | PLRX |
|---|---|---|
| Price | $1.09 | $0.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $3.13 | $2.67 |
| AVG Volume (30 Days) | 127.3K | ★ 377.2K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.88 |
| 52 Week High | $11.90 | $1.95 |
Technical Indicators
Market Signals| Indicator | TLPH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 33.52 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.13 | $1.37 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 34.38 | 7.69 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.